---
schema_version: "secwatch.filing_event.v1"
accession: "0001645113-24-000009"
form_type: "8-K"
ticker: "NVCR"
cik: "0001645113"
company_name: "NovoCure Ltd"
filed_at: "2024-03-27T23:59:59+00:00"
generated_at: "2026-06-04T07:12:30.422244+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Novocure METIS Phase 3 trial meets primary endpoint; intracranial progression delay 21.9 vs 11.3 months

## Summary
- TTFields + supportive care showed median time to intracranial progression of 21.9 months vs 11.3 months for supportive care alone (HR=0.67, p=0.016).
- Key secondary endpoints (neurocognitive failure, overall survival, radiological response) did not reach statistical significance.
- Median TTFields therapy duration was 16 weeks, median usage 67%; therapy well-tolerated with sustained quality of life.
- Novocure plans to submit data to regulatory authorities and publish findings in a peer-reviewed journal.
- Phase 3 METIS trial enrolled 298 patients with 1-10 brain metastases from NSCLC following stereotactic radiosurgery.

## SEC filing metadata
- accession: 0001645113-24-000009
- form_type: 8-K
- ticker: NVCR
- cik: 0001645113
- company_name: NovoCure Ltd
- filed_at: 2024-03-27T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645113/000164511324000009/0001645113-24-000009-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645113/000164511324000009/nvcr-20240327.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001645113-24-000009
- JSON: https://secwatch.observer/filing/0001645113-24-000009.json
- Plain text: https://secwatch.observer/filing/0001645113-24-000009.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.